Vaccine- and Immune-Based Therapy in Chronic Lymphocytic Leukemia

Seminars in Oncology

Volumn 33, Issue 2, 2006, Pages 220-229

  Le Dieu, Rifca ^a   Gribben, John ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALEMTUZUMAB; APOLIZUMAB; BEVACIZUMAB; BUSULFAN; CARRIER PROTEIN; CD40 LIGAND; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; EPRATUZUMAB; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN IDIOTYPE; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LAMININ RECEPTOR; LUMILIXIMAB; MELPHALAN; ONCOFETAL ANTIGEN; PARVOVIRUS VECTOR; PSEUDOMONAS EXOTOXIN; RICIN; RITUXIMAB; SURVIVIN; THYMOCYTE ANTIBODY; TUMOR ANTIGEN; UNINDEXED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG FATALITY; GENE DELIVERY SYSTEM; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; KIDNEY CARCINOMA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE; LYMPHOCYTOPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; SKIN MANIFESTATION; STEM CELL TRANSPLANTATION; T CELL DEPLETION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VIRUS GENE; WHOLE BODY RADIATION;

ANIMALS; ANTIGEN PRESENTATION; B-LYMPHOCYTES; CANCER VACCINES; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33646010349     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.012     Document Type: Article

References (100)

1. Hewitt H.B., Blake E.R., and Walder A.S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 33 (1976) 241-259
2. Rosenberg S.A., Lotze M.T., Muul L.M., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313 (1985) 1485-1492
3. Gitelson E., Hammond C., Mena J., et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 9 (2003) 1656-1665
4. Juffs H., Fowler N., Saal R., et al. B cell chronic lymphocytic leukemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-gamma. Pathology 36 (2004) 69-76
5. Williams J.F., Petrus M.J., Wright J.A., et al. fas-mediated lysis of chronic lymphocytic leukemia cells. Role of type I versus type II cytokines and autologous fasL-expressing T cells. Br J Haematol 107 (1999) 99-105
6. Foa R., Giovarelli M., Jemma C., et al. Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia. Evidence that normally released IL 2 is absorbed by the neoplastic B cell population. Blood 66 (1985) 614-619
7. Totterman T.H., Carlsson M., Simonsson B., et al. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 74 (1989) 786-792
8. + tumor cells in B chronic lymphocytic leukemia. Blood 91 (1998) 4273-4281
9. Rezvany M.R., Jeddi-Tehrani M., Osterborg A., et al. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia. Major perturbations are preferentially seen within the CD4 T-cell subset. Blood 94 (1999) 1063-1069
10. Farace F., Orlanducci F., Dietrich P.Y., et al. T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol 153 (1994) 4281-4290
11. Goolsby C.L., Kuchnio M., Finn W.G., et al. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population. Cytometry 42 (2000) 188-195
12. Cantwell M, Hua T, Pappas J, et al: Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3:984-989.
13. Rossi E., Matutes E., Morilla R., et al. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 10 (1996) 494-497
14. Gorgun G., Holderried T.A., Zahrieh D., et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115 (2005) 1797-1805
15. Scrivener S., Goddard R.V., Kaminski E.R., et al. Abnormal T-cell function in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 44 (2003) 383-389
16. hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106 (2005) 2018-2025
17. Heilmann E., Witting C., and Starcke A. Clinical treatment of chronic lymphatic leukemia by means of extracorporeal blood irradiation. Folia Haematol Int Mag Klin Morphol Blutforsch 105 (1978) 338-341
18. Muller C.P., Treiber D., Steinke B., et al. Enhanced antigenicity of autologous leukemia cells enriched with cholesterylhemisuccinate. Anticancer Res 11 (1991) 925-930
19. Ranheim E.A., and Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 177 (1993) 925-935
20. Yellin M.J., Sinning J., Covey L.R., et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 153 (1994) 666-674
21. Van den Hove L.E., Van Gool S.W., Vandenberghe P., et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 11 (1997) 572-580
22. Buhmann R., Nolte A., Westhaus D., et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy. Stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 93 (1999) 1992-2002
23. Krackhardt A.M., Harig S., Witzens M., et al. T-cell responses against chronic lymphocytic leukemia cells. Implications for immunotherapy. Blood 100 (2002) 167-173
24. Hoogendoorn M., Wolbers J.O., Smit W.M., et al. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators. Implications for adoptive immunotherapy. Leukemia 18 (2004) 1278-1287
25. Kater A.P., Evers L.M., Remmerswaal E.B., et al. CD40 stimulation of B-cell chronic lymphocytic leukemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 127 (2004) 404-415
26. Gricks C.S., Zahrieh D., Zauls A.J., et al. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 104 (2004) 4002-4009
27. Brentjens R.J., Latouche J.B., Santos E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9 (2003) 279-286
28. Cheadle E.J., Gilham D.E., Thistlethwaite F.C., et al. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol 129 (2005) 322-332
29. Arditti F.D., Aviner S., Dekel B., et al. Eradication of B-CLL by autologous and allogeneic host nonreactive anti-third-party CTLs. Blood 105 (2005) 3365-3371
30. Bonyhadi M., Frohlich M., Rasmussen A., et al. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol 174 (2005) 2366-2375
31. Janeway Jr. C.A., Sakato N., and Eisen H.N. Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci U S A 72 (1975) 2357-2360
32. Bogen B., Malissen B., and Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 16 (1986) 1373-1378
33. Campbell M.J., Carroll W., Kon S., et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 139 (1987) 2825-2833
34. George A.J., Folkard S.G., Hamblin T.J., et al. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol 141 (1998) 2168-2174
35. Kwak L.W., Campbell M.J., Czerwinski D.K., et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327 (1992) 1209-1215
36. Hsu F.J., Caspar C.B., Czerwinski D., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-Long-term results of a clinical trial. Blood 89 (1997) 3129-3135
37. Trojan A., Schultze J.L., Witzens M., et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6 (2000) 667-672
38. Harig S., Witzens M., Krackhardt A.M., et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 98 (2001) 2999-3005
39. Tao M.H., and Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362 (1993) 755-758
40. Bendandi M., Gocke C.D., Kobrin C.B., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5 (1999) 1171-1177
41. Czuczman M.S., Class K., and Scheinberg D.A. Interleukin-4 priming enhances a target for human complement-mediated cytotoxicity of CLL. Leukemia 7 (1993) 1020-1025
42. Siegel S., Wagner A., Kabelitz D., et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102 (2003) 4416-4423
43. Reker S., Meier A., Holten-Andersen L., et al. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 3 (2004) 173-179
44. Wang Z., Zhang Y., Mandal A., et al. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin Cancer Res 10 (2004) 6544-6550
45. Krackhardt A.M., Witzens M., Harig S., et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100 (2002) 2123-2131
46. Spaner D.E., Hammond C., Mena J., et al. A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia. Cancer Immunol Immunother 54 (2005) 635-646
47. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
48. Brossart P., and Bevan M.J. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells. Pathway of presentation and regulation by cytokines. Blood 90 (1997) 1594-1599
49. Brossart P., Wirths S., Brugger W., et al. Dendritic cells in cancer vaccines. Exp Hematol 29 (2001) 1247-1255
50. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
51. Thurner B., Haendle I., Roder C., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190 (1999) 1669-1678
52. Murphy G.P., Tjoa B.A., Simmons S.J., et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides. A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38 (1999) 73-78
53. Murphy G.P., Tjoa B.A., Simmons S.J., et al. Phase II prostate cancer vaccine trial. Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39 (1999) 54-59
54. Kugler A., Stuhler G., Walden P., et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6 (2000) 332-336
55. Fong L., Hou Y., Rivas A., et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 98 (2001) 8809-8814
56. Timmerman J.M., Czerwinski D.K., Davis T.A., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma. Clinical and immune responses in 35 patients. Blood 99 (2002) 1517-1526
57. Goddard R.V., Prentice A.G., Copplestone J.A., et al. Generation in vitro of B-cell chronic lymphocytic leukemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumor cell lysate. Clin Exp Immunol 126 (2001) 16-28
58. Muller M.R., Tsakou G., Grunebach F., et al. Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 103 (2004) 1763-1769
59. Goddard R.V., Prentice A.G., Copplestone J.A., et al. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin Exp Immunol 131 (2003) 82-89
60. Kokhaei P., Rezvany M.R., Virving L., et al. Dendritic cells loaded with apoptotic tumor cells induce a stronger T-cell response than dendritic cell-tumor hybrids in B-CLL. Leukemia 17 (2003) 894-899
61. Hus I., Rolinski J., Tabarkiewicz J., et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19 (2005) 1621-1627
62. Mocikat R., Selmayr M., Thierfelder S., et al. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity. Cancer Res 57 (1997) 2346-2349
63. Wahl U., Nossner E., Kronenberger K., et al. Vaccination against B-cell chronic lymphocytic leukemia with trioma cells. preclinical evaluation. Clin Cancer Res 9 (2003) 4240-4246
64. Takahashi S., Rousseau R.F., Yotnda P., et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 12 (2001) 659-670
65. Wendtner C.M., Kofler D.M., Theiss H.D., et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 100 (2002) 1655-1661
66. Tolba K.A., Bowers W.J., Hilchey S.P., et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood 98 (2001) 287-295
67. Biagi E., Dotti G., Yvon E., et al. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood 105 (2005) 2436-2442
68. Wierda W.G., Cantwell M.J., Woods S.J., et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96 (2000) 2917-2924
69. Spaner D.E., Hammond C., Mena J., et al. Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukemia cells. Implications for immunotherapy. Br J Haematol 127 (2004) 531-542
70. Ehrlich P. The Croonian Lecture. "On immunity with special reference to cell life. " Proc R Soc 66 (1900) 424-448
71. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma. Half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
72. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001) 2153-2164
73. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 (2001) 2165-2170
74. Hainsworth J.D., Litchy S., Barton J.H., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 (2003) 1746-1751
75. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine. Results of a large international study. Blood 99 (2002) 3554-3561
76. Stilgenbauer S., and Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347 (2002) 452-453
77. Byrd J., Peterson B., and Park K. Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia. Preliminary results from CALGB 9712. Proc Am Soc Clin Oncol 20 (2001) 280a (abstr 1116)
78. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4079-4088
79. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4070-4078
80. Kennedy B., Rawstron A., Carter C., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99 (2002) 2245-2247
81. Rai K.R., Byrd J.C., Peterson B., et al. A phase II trial of fludarabine followed by alemtuzumab (CAMPATH-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease. Cancer and Leukemia Group B (CALGB) study 19901. Blood 100 (2002) 205a (abstr 772)
82. Faderl S., and O'Brien S. Combined use of alemtuzumab and rituximab in patients with relapsed or refractory chronic lymphoid malignancies. An update of the M.D. Anderson experience. Blood 100 (2002) 206a (abstr 775)
83. Reusch U., Le Gall F., Hensel M., et al. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int J Cancer 112 (2004) 509-518
84. Kreitman R.J., Wilson W.H., Bergeron K., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345 (2001) 241-247
85. LeMaistre C.F., Meneghetti C., Rosenblum M., et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79 (1992) 2547-2554
86. Fleming D.R., Powell B.L., and Patrick C.L. Diphtheria fusion protein ONTAK therapy of patients with fludarabine refractory chronic lymphocytic leukemia. Proc Am Soc Clin Oncol 19 (2002) 268a (abstr 1071)
87. Jarque I., Palau J., Sanz G.F., et al. Delayed complete response after allogeneic bone marrow transplantation in chronic lymphocytic leukemia. Blood 82 (1993) 1036-1038
88. Mehta J., Powles R., Singhal S., et al. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease. Possible role of graft-versus-leukemia. Bone Marrow Transplant 17 (1996) 371-375
89. Rondon G., Giralt S., Huh Y., et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18 (1996) 669-672
90. Michallet M., Archimbaud E., Bandini G., et al., European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 124 (1996) 311-315
91. Ritgen M., Stilgenbauer S., von Neuhoff N., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status. Implications of minimal residual disease measurement with quantitative PCR. Blood 104 (2004) 2600-2602
92. Ritgen M., Dreger P., Humpe A., et al. Quantitative PCR demonstrates effective graft versus leukemia activity after allogeneic stem cell transplantation using reduced intensity conditioning in patients with chronic lymphocytic leukemia. Blood 100 (2002) 854a (abstr)
93. Khouri I.F., Przepiorka D., van Besien K., et al. Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia. Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 97 (1997) 466-473
94. Dreger P., van Biezen A., and Brand R. Reduced-intensity conditioning lowers treatment-related mortality (TRM) of allogeneic stem cell transplantation (SCT) for CLL. A retrospective study on 448 patients. Blood 102 (2003) 197a (abstr)
95. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens. Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 (2001) 631-637
96. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite. Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 (1998) 2817-2824
97. Schetelig J., Thiede C., Bornhauser M., et al., The Cooperative German Transplant Study Group. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation. J Clin Oncol 21 (2003) 2747-2753
98. Dreger P., Brand R., Hansz J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17 (2003) 841-848
99. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 3819-3829
100. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104 (2004) 3865-3871